The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer.
M. Schirripa
No relevant relationships to disclose
F. Loupakis
No relevant relationships to disclose
C. Caparello
No relevant relationships to disclose
N. Funel
No relevant relationships to disclose
L. Pollina
No relevant relationships to disclose
E. Vasile
No relevant relationships to disclose
C. Cremolini
No relevant relationships to disclose
L. Salvatore
No relevant relationships to disclose
G. Masi
No relevant relationships to disclose
L. Fornaro
No relevant relationships to disclose
D. Campani
No relevant relationships to disclose
A. Falcone
No relevant relationships to disclose